全文获取类型
收费全文 | 127163篇 |
免费 | 7218篇 |
国内免费 | 1093篇 |
专业分类
耳鼻咽喉 | 1952篇 |
儿科学 | 1917篇 |
妇产科学 | 1872篇 |
基础医学 | 20238篇 |
口腔科学 | 3074篇 |
临床医学 | 11786篇 |
内科学 | 22740篇 |
皮肤病学 | 3971篇 |
神经病学 | 10313篇 |
特种医学 | 7290篇 |
外科学 | 16648篇 |
综合类 | 653篇 |
现状与发展 | 3篇 |
一般理论 | 27篇 |
预防医学 | 6692篇 |
眼科学 | 3193篇 |
药学 | 11399篇 |
中国医学 | 1455篇 |
肿瘤学 | 10251篇 |
出版年
2023年 | 904篇 |
2022年 | 2716篇 |
2021年 | 4393篇 |
2020年 | 2105篇 |
2019年 | 2943篇 |
2018年 | 3675篇 |
2017年 | 2988篇 |
2016年 | 3899篇 |
2015年 | 5439篇 |
2014年 | 6442篇 |
2013年 | 7500篇 |
2012年 | 11250篇 |
2011年 | 10776篇 |
2010年 | 6169篇 |
2009年 | 5306篇 |
2008年 | 7546篇 |
2007年 | 7162篇 |
2006年 | 6482篇 |
2005年 | 5987篇 |
2004年 | 5224篇 |
2003年 | 4544篇 |
2002年 | 3911篇 |
2001年 | 3047篇 |
2000年 | 2793篇 |
1999年 | 2145篇 |
1998年 | 928篇 |
1997年 | 694篇 |
1996年 | 527篇 |
1995年 | 455篇 |
1994年 | 398篇 |
1993年 | 335篇 |
1992年 | 749篇 |
1991年 | 700篇 |
1990年 | 642篇 |
1989年 | 562篇 |
1988年 | 472篇 |
1987年 | 467篇 |
1986年 | 335篇 |
1985年 | 375篇 |
1984年 | 262篇 |
1983年 | 194篇 |
1982年 | 134篇 |
1981年 | 173篇 |
1980年 | 131篇 |
1979年 | 222篇 |
1978年 | 165篇 |
1976年 | 133篇 |
1975年 | 123篇 |
1974年 | 139篇 |
1973年 | 119篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Young Ho Yun Chang Geol Lee Si-young Kim Sang-wook Lee Dae Seog Heo Jun Suk Kim Keun Seok Lee Young Seon Hong Jung Suk Lee Chang Hoon You 《Journal of clinical oncology》2004,22(2):307-314
PURPOSE:To ascertain the attitude of cancer patients and their families toward disclosure of terminal illness to the patient. PATIENTS AND METHODS: We constructed a questionnaire that included demographic and clinical information and delivered it to 758 consecutive individuals (433 cancer patients and 325 families that have a relative with cancer) at seven university hospitals and one national cancer center in Korea. RESULTS: 380 cancer patients and one member from each of 281 families that have a relative with cancer completed the questionnaire. Cancer patients were more likely than family members to believe that patients should be informed of the terminal illness (96.1% v 76.9%; P <.001). Fifty percent of the family members and 78.3% of the patients thought that the doctor in charge should be the one who informs the patient. Additionally, 71.7% of the patients and 43.6% of the family members thought that patients should be informed immediately after the diagnosis. Stepwise multiple logistic regression indicated that the patient group was more likely than the family group to want the patient to be informed of the terminal illness (odds ratio [OR], 9.76; 95% CI, 4.31 to 22.14), by the doctor (OR, 4.00; 95% CI, 2.61 to 6.11), and immediately after the diagnosis (OR, 3.64; 95% CI, 2.45 to 5.41). CONCLUSION: Our findings indicated that most cancer patients want to be informed if their illness is terminal, and physicians should realize that the patient and the family unit may differ in their attitude toward such a disclosure. Our results also reflect the importance of how information is given to the patient. 相似文献
992.
Nita L Seibel Sierra Li Norman E Breslow J Bruce Beckwith Daniel M Green Gerald M Haase Michael L Ritchey Patrick R M Thomas Paul E Grundy Jerry Z Finklestein Tae Kim Stephen J Shochat Panayotis P Kelalis Giulio J D'Angio 《Journal of clinical oncology》2004,22(3):468-473
PURPOSE: To evaluate the effect of conventional and standard (ST) versus pulse-intensive (PI) chemotherapy and short-duration versus long-duration chemotherapy on relapse-free survival (RFS) and overall survival rates of patients with clear-cell sarcoma of the kidney (CCSK) entered onto the National Wilms' Tumor Study (NWTS)-4. PATIENTS AND METHODS: The 5-year and 8-year RFS rates were determined for patients with CCSK treated on the NWTS-4. After August 6, 1986, 40 previously untreated children younger than 16 years with CCSK were randomly assigned, after the completion of 6 months of chemotherapy, to discontinue (short) or continue 9 additional months (long) of treatment with chemotherapy regimens that included vincristine and either divided-dose (ST) courses (5 days) or single-dose (PI) treatment with dactinomycin and divided-dose (ST) courses (3 days) or single-dose (PI) treatment with doxorubicin. RESULTS: For patients with CCSK, the 5- and 8-year RFS rates were 65.2% and 60.6%, respectively, for patients randomly assigned to the short chemotherapy and 87.8% (both 5- and 8-year RFS) for patients randomly assigned to the long chemotherapy (P =.08). The overall survival rates for patients at 5 and 8 years were 95.5% and 85.9%, respectively, for the short chemotherapy and 87.5% (both 5- and 8-year overall survival) for the long chemotherapy (P =.99). In NWTS-4, the overall survival rates for patients with CCSK improved from NWTS-3 (83% v 66.9% at 8 years, respectively; P <.01). CONCLUSION: CCSK patients exhibit an improved RFS from a longer course of therapy when using vincristine, doxorubicin, and dactinomycin, but their long-term survival is unchanged compared with patients receiving 6 months of therapy. The overall survival rates for patients with CCSK have improved from NWTS-3. 相似文献
993.
Sandra J Horning Edie Weller KyungMann Kim John D Earle Michael J O'Connell Thomas M Habermann John H Glick 《Journal of clinical oncology》2004,22(15):3032-3038
PURPOSE: To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-stage aggressive lymphoma patients achieving complete remission (CR) after chemotherapy, and to measure conversion from partial response (PR) to CR with high-dose (40 Gy) RT. PATIENTS AND METHODS: From 1984 to 1992, stage I (with risk factors) and II adults with diffuse aggressive lymphoma in CR after eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) were randomly assigned to 30 Gy involved-field RT or OBS. PR patients received 40 Gy RT. RESULTS: Among 172 CR patients, the 6-year disease-free survival (DFS) was 73% for low-dose RT versus 56% for OBS (two-sided P = .05). Failure-free survival (two-sided P = .06), and time to progression (two-sided P = .06) also favored RT. Intent-to-treat analyses yielded similar results. No survival differences were observed. Three RT versus 15 OBS patients relapsed in initial disease sites. At 6 years, failure-free survival was 63% in PR patients; conversion to CR did not significantly influence clinical outcome. CONCLUSION: For patients in CR after CHOP, low-dose RT prolonged DFS and provided local control, but no survival benefit was observed. The majority of PR patients were event-free at 6 years despite residual radiographic abnormalities. Future efforts should be directed toward improved imaging and more effective systemic therapies. 相似文献
994.
Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. 总被引:16,自引:0,他引:16
Tae Won Kim Hyoungnam Lee Yoon-Koo Kang Mi Sun Choe Min-Hee Ryu Heung Moon Chang Jung Sun Kim Jeong Hwan Yook Byung Sik Kim Jung Shin Lee 《Clinical cancer research》2004,10(9):3076-3081
PURPOSE: Constitutive mutational activation of c-kit has been found to be associated with the pathogenesis of gastrointestinal stromal tumors (GISTs). The prognostic significance of c-kit mutations, however, is still controversial. EXPERIMENTAL DESIGN: We examined 86 patients curatively resected for localized GIST. Genomic DNA was extracted from paraffin-embedded tumor tissues. Exons 9, 11, 13, and 17 of the c-kit gene were amplified by PCR and sequenced. RESULTS: Mutations in exon 11 were detected in 61 tumors, and mutations in exon 9 were observed in three tumors, whereas no mutations were detected in exons 13 or 17. The overall c-kit mutation frequency was 74%. Amino acid alterations in the 61 tumors with exon 11 mutations were deletion in 33 tumors, substitution in 20, both deletion and substitution in 4, insertion in 1, and duplication in 3. Histologically, tumors with c-kit mutations showed higher mitotic counts and higher cellularity. The 5-year relapse-free survival (RFS) in patients having GISTs with c-kit mutations was 21%, compared with 60% in those without c-kit mutations. Significantly higher RFS rates were observed in patients with tumors having mitotic counts < 5 mitoses/50 high power field, spindle-cell histology, tumor size < 5 cm, or gastric GISTs. Multivariate analyses indicated association of poorer RFS with a higher mitotic count > or = 5 of 50 high power fields; odds ratio (OR) = 3.0], presence of c-kit mutations (OR = 5.6), and a larger tumor size (> or = 5 cm; OR = 4.2). CONCLUSIONS: The presence of c-kit mutation, along with high mitotic count and larger tumor size, was an independent factor for poor prognosis in patients with localized GISTs. 相似文献
995.
996.
997.
Kim WR Badley AD Wiesner RH Porayko MK Seaberg EC Keating MR Evans RW Dickson ER Krom RA Paya CV 《Transplantation》2000,69(3):357-361
BACKGROUND: We studied the economic impact of cytomegalovirus (CMV) disease and its effective reduction with antiviral prophylaxis in liver transplant recipients. METHOD: Analysis of institutional charge data accumulated during a prospective, randomized, controlled trial comparing oral acyclovir 800 mg four times daily for 120 days (ACV) and intravenous ganciclovir 5 mg/kg every 12 h for 14 days followed by ACV for 106 days (GCV) was performed. RESULTS: Liver transplant recipients who developed CMV disease had significantly higher charges (median: $148,300) than those who developed asymptomatic CMV infection ($119,600) or experienced no CMV infection ($114,100) (P<0.01). A multiple linear regression analysis indicated that CMV disease is associated with a 49% increase in charges, independent of other factors influencing increased hospitalization charges. In CMV-seronegative patients who received a CMV-seropositive donor organ, GCV prophylaxis was associated with a significant reduction in charges, as compared to ACV prophylaxis ($113,900 vs. $153,300, respectively; P=0.02). CONCLUSIONS: CMV disease is an independent risk factor for increased resource utilization associated with liver transplantation. The use of an effective prophylactic antiviral regimen provides savings in health care resources, particularly in patients at high risk for developing CMV disease. 相似文献
998.
999.
1000.
An effective in vitro protocol for the investigation of thrombogenicity can provide many advantages in the development of mechanical circulatory assist devices. Strict avoidance of air contact with blood recently was proposed for reliable in vitro evaluation. This study was performed to confirm the necessity of avoidance of air contact for the in vitro test of thrombogenicity in a rotary pump. Two sets of mock circuits with the same rotary blood pumps, reservoirs, and connecting tubes were made. In one system, blood came in contact with air while the other did not. The test blood was heparinized at the dose of 1 IU per 1 ml of blood. The tests were terminated at an activated coagulation time of 1.5 times the control value. The levels of hematocrit, platelet, factors VIII and XII, fibrinogen, thromboxane B2, and plasma-free hemoglobin were measured during the procedures. After the experiments, the thrombi formed were observed, measured, and compared with those formed in in vivo circumstances. The tests were repeated 12 times. There were no statistically significant differences between the 2 groups in hematologic parameters and the amounts of thrombi formed. The thrombi observed in both groups showed the same pathologic findings as those formed in vivo with the exception of intermittent multiple air bubbles found in thrombi of the air-contact group. In conclusion, the effect of air contact in the in vitro investigation of thrombogenicity was negligible while the proposed in vitro test models of thrombogenesis in the mechanical circulatory assist device proved to be reliable. 相似文献